Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Resolor prucalopride: Phase III data

In a double-blind Phase III trial in 713 patients, 2 and 4 mg of oral Resolor met the primary endpoint of achieving >=3 SCBMs

Read the full 243 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE